Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EHang Holdings Ltd - ADR (EH) vs Zoetis Inc (ZTS) Price & Performance

EHang Holdings Ltd - ADRTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

EHang Holdings Ltd - ADR vs Zoetis Inc — how do they compare? EHang Holdings Ltd - ADR trades at $4.14 (market cap $309.45M), while Zoetis Inc trades at $74.42 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 97.6× EHang Holdings Ltd - ADR's market cap, and Zoetis Inc pays a 2.9% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold EHang Holdings Ltd - ADR for 46 Days and Zoetis Inc for 70 Days on average.

EHZTS
Market Cap
$309.45M$30.20B
Volume
765,7996,175,327
Sector
IndustrialsHealth
52-Week High
$18.94$147.53
52-Week Low
$4.03$69.09
Typical Hold Time
46 Days70 Days
Enterprise Value
$261.14M$37.76B
Dividend Yield
—2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EHang Holdings Ltd - ADR

EHang Holdings Limited (EH) trades at $4.14, showing no recent price movement. The stock is technically bearish with moving averages signaling a downtrend. Fundamentally, the company reported a net loss of $275.98 million on $417.98 million revenue in 2025, with negative profit margins and returns. Recent news includes expansion of its Global Fast Track Program to Vietnam but also multiple law firm investigations into investor claims.

The outlook remains challenging with persistent losses and regulatory scrutiny. Investment opportunities hinge on successful commercialization of eVTOL technology, but risks include high cash burn, negative earnings, and legal uncertainties. Analyst consensus is mixed with 20% buy, 40% hold, and 40% sell ratings, reflecting cautious sentiment.

Zoetis Inc

Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.

The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EH
100% Buy0% Sell
Avg holding period · 46 Days
ZTS

No sentiment data available yet.

Top news

Latest headlines on both assets

About EHang Holdings Ltd - ADR

EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.

Read more on EH →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →